Factsheet - MorphoSys

Factsheet
July 2013
Engineering the Medicines of Tomorrow
The Company
MorphoSys is a biotechnology company focused on the develop -
ment of antibodies. Using its proprietary techno logies, the Company
develops and commercializes high-quality antibodies for
therapeutic applications. By combining in-house development
with selected alliances, MorphoSys has built one of the industry’s
broadest pipelines of therapeutic antibody candi dates. Proprietary
technologies are used to develop innovative compounds
on MorphoSys’s own responsibility and in collaboration with
partners. The cooperations generate constant cash flows which
are invested in the development of the Company’s proprietary
antibody portfolio. This sound financial performance dis tin gui shes
MorphoSys from many other companies in the industry.
Business Strategy
MorphoSys operates in two business segments. The Partnered
Discovery segment operates in partnerships with pharmaceutical
and biotechnology companies, applying the Company’s proprietary
technologies to generate new drug candidates. While
the development costs are borne by the partner, MorphoSys
secures research funding and technology license fees, and stands
to benefit from successful programs through mile stone payments
and royalties on product sales. By way of example, the Company’s
strategic alliance with Novartis is one of the largest R&D
agreements ever signed in the pharma ceutical industry. The
second segment, Proprietary Development, also operates in the
pharmaceutical industry. In this segment MorphoSys uses its
proprietary technologies to develop new therapeutic antibody
candidates on its own responsibility and to partner them at a
certain stage of clinical testing. The focus is on indications such
as inflammatory and autoimmune diseases, as well as oncology.
In each program there is a clear focus on in novative approaches
to diseases which are currently not well-treated.
Technologies
MorphoSys’s success is based on its strong technologies, comprising
several billion distinct, fully human antibodies which
can be optimized for specific applications. Currently, more than
80 therapeutic antibodies derived from HuCAL are in development.
In total, 21 programs in MorphoSys’s pipeline are in clinical
testing.
Through its 2010 acquisition of Sloning BioTechnology,
MorphoSys became the sole source of Sloning’s state-of-the-art
Slonomics technology, which dramatically improves the assembly
and quality of protein libraries. This technology is used to
accelerate the generation of therapeutic antibodies and is at
the core of MorphoSys’s newest antibody technology Ylanthia.
Ylanthia was specifically designed to overcome current
limitations in therapeutic antibody development, including
challenges associated with certain target classes, limited diversity,
poor biophysical properties and difficult production.
In 2012, MorphoSys launched its "Innovation Capital" initiative
through which the Company invests in promising start-ups
with technologies and product candidates being close to its areas
of interest. MorphoSys seeks to combine the classical cor porate
venture approach with collaborative elements. In 2012, MorphoSys
announced a first collaboration in this area with Lanthio
Pharma, a biopharmaceutical company focused on discovering
and developing lantipeptides.
MORPHOSYS AG
n Stock Exchange Frankfurt, Germany, TecDAX 30
n Security Code Number MOR/663200
n ISIN DE 0006632003
n U.S. Security Code (Cusip) 617760103 (MPSYY)
n No. of Shares Issued (June 30, 2013) 23,400,632
n No. of Employees (June 30, 2013) 290
n Revenues* 2012 (IFRS) EUR 51.9 million
n Net Profit* 2012 (IFRS) EUR 1.9 million
n Diluted Net Profit per Share* 2012 (IFRS) EUR 0.10
* continued operations

Product Pipeline
Program, Partner Indication Discovery Pre-clinic Phase 1 Phase 2 Phase 3 Market
MOR10 3, GSK Rheumatoid Arthritis
MOR208 B-cell Malignancies
MOR10 3, GSK Multiple Sclerosis
MOR202, Celgene/MOR Multiple Myeloma
Gantenerumab, Roche Alzheimer’s Disease
Guselkumab, Janssen/J&J Psoriasis
Guselkumab, Janssen/J&J Rheumatoid Arthritis
BHQ880, Novartis Cancer
BYM338, Novartis Musculoskeletal
NOV-3, Novartis n. d.
LGF316, Novartis Ophthalmology
OMP-59R5, OncoMed Cancer
BAY94-9343, Bayer HealthCare Cancer
BI-1, Boehringer Ingelheim n. d.
CNTO 3157, Janssen/J&J Asthma
CNTO-5, Janssen/J&J Inflammation
VAY736, Novartis Inflammation
LJM716, Novartis Cancer
Vantictumab, OncoMed Cancer
PFE-1, Pfizer Cancer
NOV-7, Novartis Ophthalmology
1. Partnered Products
MorphoSys’s partnered product pipeline comprises more than
70 antibody programs covering a range of indications. The pipeline
spans a number of successful partnerships which have been
established over the last 12 years since the HuCAL technology
was introduced. Of the programs in development, 17 are pre -
sently in human clinical trials and around 20 in preclinical
evaluation.
2. Proprietary Products
MorphoSys develops proprietary therapeutic antibody candidates
in the areas of inflammation and oncology. By conducting
the discovery, pre-clinical and early clinical development itself,
MorphoSys is building a valuable portfolio of proprietary drugs.
Currently, the proprietary product portfolio comprises the following
clinical stage programs, two of which MorphoSys could
partner successfully in 2013:
MOR103 (GlaxoSmithKline)
In June 2013 MorphoSys signed a global agreement with GlaxoSmithKline
(GSK) to develop and commercialize MOR103.
MOR103 is a HuCAL antibody directed against GM-CSF, a thera -
peutic target for the treatment of inflammatory diseases that
has great potential in a number of indications where current
treat ments are inadequate. A clinical phase 1b/2a study in
patients with RA has been completed and reported excellent
data on safety and efficacy in September 2012. In addition to
CONTACT
MorphoSys AG
Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
Phone: +49 (0) 89 899 27-0
Fax: +49 (0) 89 899 27-222
Email: info@morphosys.com
Website: www.morphosys.com
the RA trial, MOR103 is currently being tested in a phase 1b trial
in patients with multiple sclerosis.
MOR202 (Celgene)
In July 2013 MorphoSys and Celgene signed an agreement to
jointly develop MOR202 globally and to co-promote MOR202 in
Europe. MOR202 is a HuCAL antibody directed against CD38, a
promising therapeutic target for the treatment of multiple myeloma
and certain leukemias. MOR202 is currently being tested
in a phase 1/2a trial in multiple myeloma patients.
MOR208
MOR208 is a humanized monoclonal antibody in-licensed from
Xencor, which targets the antigen CD19. The antibody incor -
porates an optimized Fc portion, which further enhances its ability
to kill malignant CD-19-bearing B-cells. MOR208 is being
developed for the treatment of B-cell malignancies and autoimmune
diseases. The program has concluded a phase 1 trial in
patients with CLL and is now being evaluated in two phase 2
studies in ALL and NHL.
Management
Management Board
Dr. Simon E. Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Arndt Schottelius, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer
HuCAL ® , HuCAL GOLD ® , HuCAL PLATINUM ® , CysDisplay ® , RapMAT ® , arYla ® , Ylanthia ® and 100 billion high potentials ® are registered trademarks of MorphoSys AG.
Slonomics ® 2013 July
is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG. Version::